Differences in HIV-1 reservoir size, landscape characteristics, and decay dynamics in acute and chronic treated HIV-1 Clade C infection
Persisting HIV reservoir viruses in resting CD4 T cells and other cellular subsets are a barrier to cure efforts. Early antiretroviral therapy (ART) enables post-treatment viral control in some cases, but mechanisms remain unclear. We hypothesised that ART initiated before peak viremia impacts HIV-1 subtype C reservoirs. We studied 35 women at high risk of infection from Durban, South Africa, identified with hyperacute HIV by twice-weekly HIV-RNA testing. Participants included 11 starting ART at a median of 456 (297–1203) days post-onset of viremia (DPOV) and 24 at 1 (1–3) DPOV. Peripheral blood mononuclear cells (PBMCs) were used to measured total HIV-1 DNA by droplet digital PCR (ddPCR) and sequence viral reservoir genomes by full-length proviral sequencing (FLIP-seq). ART during hyperacute infection blunted peak viremia (p<0.0001), but contemporaneous total HIV-1 DNA did not differ (p=0.104). Over 1 year, a decline of total HIV-1 DNA was observed in early treated persons (p=0.0004), but not late treated. Among 697 viral genome sequences, the proviral genetic landscape differed between untreated, late treated, and early treated groups. Intact genomes after 1 year were higher in untreated (31%) versus late treated (14%) and early treated (0%). Treatment in both late and early infection caused more rapid decay of intact (13% and 51% per month) versus defective (2% and 35%) viral genomes. However, intact genomes persisted 1 year post chronic treatment but were undetectable with early ART. Early ART also reduced phylogenetic diversity of intact genomes and limited cytotoxic T lymphocyte immune escape variants in the reservoir. Overall, ART initiated in hyperacute HIV-1 subtype C infection did not impact reservoir seeding but was associated with rapid intact viral genome decay, reduced genetic complexity, and limited immune escape, which may accelerate reservoir clearance in combination with other interventional strategies.
Authors
- Guinevere Q. Lee (ORCID: https://orcid.org/0000-0002-9412-886X)
- Kavidha Reddy (ORCID: https://orcid.org/0000-0002-7024-0574)
- Bruce D. Walker (ORCID: https://orcid.org/0000-0001-6122-9245)
- Mathias Lichterfeld (ORCID: https://orcid.org/0000-0001-9865-8350)
- Thumbi Ndung’u (ORCID: https://orcid.org/0000-0003-2962-3992)
- Xu G. Yu (ORCID: https://orcid.org/0000-0002-8295-884X)
- Tatenda JB Chikowore
- Krista L. Dong (ORCID: https://orcid.org/0000-0002-2038-3518)
- Nicole Reddy
- Kathy Baisley
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Cornell University (US)
- Ragon Institute of MGH, MIT and Harvard (US)
- London School of Hygiene & Tropical Medicine (GB)
- Africa Health Research Institute (ZA)
- University College London (GB)
- University of KwaZulu-Natal (ZA)
Publication Details
- Journal
- eLife
- Published
- 2025-02-20
- DOI
- https://doi.org/10.7554/elife.96617.4
- Citations
- 8
- Primary Topic
- HIV Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 8.29
Funders
- Bill and Melinda Gates Foundation
- International AIDS Vaccine Initiative
- Gilead Sciences
- Harvard University Center for AIDS Research
- Wellcome Trust
- National Institute of Allergy and Infectious Diseases